The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment.
Comments or Questions?
The Committee on SNM Guidelines is continually developing new guidelines and reviewing and updating existing guidelines. If you have specific comments or questions on the content of any of the guidelines, or if you have suggestions for new guidelines that you feel should be written, please contact the Committee at email@example.com. All comments will be considered in the guideline development process.
SNMMI endorses these guidelines. Dosage recommendations should be taken in the context of "good practice" of nuclear medicine and do not substitute for national and international legal or regulatory provisions.
|SNMMI Approval Date||Title|
|131I-meta-iodobenzylguanidine (131I-mIBG) therapy (2008)|
|3/20/2012||131I/123I- Metaiodobenzylguanidine (MIBG) scintigraphy (2010)|
|3/20/2012||Radioimmunotherapy for B-cell lymphoma with 90Y-radiolabelled itribumomab tiuxetan (Zevalin) (2006) * Pretherapeutic imaging with 111In-ibritumomab tiuxetan is no longer mandatory in the United States.|
Regulatory Issues for EANM Guidelines
Applicable to all countries: Clinicians involved in unsealed source therapy must be knowledgeable about and compliant with all applicable national and local legislation and regulations.
Applicable in the United States: The radiopharmaceutical(s) used for the diagnostic and therapeutic procedure(s) addressed in this guideline/guidance document is/are not approved by the Food and Drug Administration (FDA)in the United States. Therefore in the United States, these procedures should be performed only by physicians holding an FDA-approved Investigational New Drug (IND) application for the radiopharmaceutical.
Please note the below guidelines have been retired and thus not updated since their last approval. Therefore, these guidelines may not reflect current knowledge and practice in the field of nuclear medicine. SNM is providing these guidelines on an 'as is' basis for general information purposes only and does not accept any responsibility for accuracy, completeness, currency, relevance, reliability or suitability of the information contained therein.
|6/23/2001||Gallium Scintigraphy in the Evaluation of Malignant Disease 3.0|
|2/7/1999||Tumor Imaging Using F-18 FDG 2.0|
|2/7/1999||Gastrointestinal Bleeding/Meckel's Diverticulum Scintigraphy 1.0|
|Guidelines Available for Public Comment|
As part of the revision or development process, the Committee on SNM Guidelines will seek public comment on draft documents in order to ensure we are creating the most accurate guidelines. To submit comments on a guideline, please download the response form and submit to Janette Merrill via email, firstname.lastname@example.org. Below are guidelines currently for which we are seeking public input: